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Abstract. Background/Aim: In the search for new derivatives
of anthracycline antibiotics, formamidinodaunorubicins
containing in the amidine group either a morpholine moiety
(DAUFmor) or a hexamethyleneimine moiety (DAUFhex)
were synthesized. The biological effects of daunorubicin
(DAU), DAUFmor and DAUFhex were compared. Materials
and Methods: The experiments were performed on human
acute lymphoblastic leukemia MOLT-4 cells and human acute
myeloblastic leukemia ML-1 cells. The research was
conducted using the spectrophotometric 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assay and the electronic Beckman-Coulter method. Results:
Temporary changes in the leukemia cell viability, size and
count were found. The antileukemic activities of the new DAU
analogs were weaker than that of daunorubicin. MOLT-4
cells were more sensitive than ML-1 cells to the action of all
agents. Among the formamidinodaunorubicins, DAUFmor
appeared to be more active in ML-1 cells than DAUFhex, but
there were not differences between the analyzed values in
MOLT-4 cells. Conclusion: The structural modifications of
daunorubicin were responsible for the different antileukemic
potentials of the two formamidinodaunorubicins. 
Anthracyclines play a key role in the treatment of many
neoplastic diseases. Structural modifications of currently
approved anthracycline antibiotics are an important way to
improve their anticancer activity. Many attempts to modify
the structure of these antibiotics have been made (1-3). For
this reason, amidinoanthracyclines which are new analogs of
anthracyclines, were synthesized. In these compounds, the
amino group (–NH2) at the C-3 position of the daunosamine
moiety was replaced by the formamidine system (–N=C–N<)
containing the rest of the cyclic amines with gradually
increasing ring size (4, 5).
Daunorubicin is the first anthracycline antibiotic which
was approved for clinical use. This agent is still widely used
in anticancer therapy. Daunorubicin has activity against acute
lymphoblastic and myeloblastic leukemias, pediatric solid
tumors and adult solid malignancies (2, 3). In the search for
‘a better anthracycline’, formamidinodaunorubicins (Figure
1) which contained either a morpholine moiety (DAUFmor)
or a hexamethyleneimine moiety (DAUFhex) in the amidine
group were synthesized (4, 5). 
Cell viability, cell size and count are accepted as being
important parameters in determining and characterizing
antileukemic activity of various chemotherapeutic agents (6-
9). Therefore, the present study was undertaken to compare
the in vitro effects of daunorubicin, DAUFmor and DAUFhex
on human acute lymphoblastic leukemia MOLT-4 cells and
human acute myeloblastic leukemia ML-1 cells. Temporary
changes in the viability, size and count of the acute leukemia
cells exposed to the three anthracycline agents were
analyzed. 
Materials and Methods
Cells. Human acute lymphoblastic leukemia MOLT-4 cells and
human acute myeloblastic leukemia ML-1 cells (European
Collection of Cell Cultures, Salisbury, Wiltshire, UK) were
maintained in RPMI-1640 medium (Gibco BRL Life Technologies,
Warsaw, Poland) supplemented with 10% fetal calf serum (Gibco
BRL Life Technologies, Warsaw, Poland), 2 mM L-glutamine
(Sigma Aldrich, Poznań, Poland), and antibiotic antimycotic
solution (AAS; Sigma Aldrich, Poznań, Poland). AAS contained 20
units of penicillin, 20 μg streptomycin and 0.05 μg amphotericin B.
Every third day, the acute leukemia cells were passaged. The cells
grew at 37˚C in an atmosphere of 5% CO2 in air (HERAcell
incubator; KendroLab, Warsaw, Poland). 
Chemicals. The three anthracycline compounds (Figure 1),
daunorubicin and two formamidinodaunorubicins DAUFmor and
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DAUFhex were synthesized at the Institute of Biotechnology and
Antibiotics (Warsaw, Poland). The formamidinodaunorubicin
compounds were obtained in the reaction of daunorubicin
hydrochloride with acetals, derivatives of N-formylamines. The
structure of the formamidinodaunorubicins were confirmed by their
1H-nuclear magnetic resonance (NMR) and 13C-NMR spectra.
According to the high preasure liquid chromatography (HPLC)
analysis, the purities of DAUFmor and DAUFhex were 98.8 and
99.2%, respectively (4). Daunorubicin, DAUFmor, and DAUFhex
were dissolved in aqua pro injectione (Polpharma, Starogard
Gdański, Poland). All solutions were freshly-prepared directly
before treatment of the acute leukemia cells. 
Anthracycline doses and cell treatment. After a dilution of the cell
suspension to a density of 15×104 cells/ml medium, MOLT-4 and
ML-1 cells were subjected to the anthracycline agent exposure.
MOLT-4 cells were exposed to DAU, DAUFmor, and DAUFhex at
concentrations of 25 nM, 50 nM, and 75 nM, respectively, and ML-1
cells to the action of these anthracycline agents applied at the
concentrations of 75 nM, 150 nM, and 225 nM, respectively. The
controls consisted of untreated MOLT-4 and ML-1 cells. The chosen
concentrations of daunorubicin, DAUFmor, and DAUFhex used in the
present studies are based on the unpublished data of our previous
experiments performed on these two human acute leukemia cell lines. 
Analyses of leukemia cells after the anthracycline application. The
temporary changes occurring in human acute lymphoblastic leukemia
MOLT-4 cells and human acute myeloblastic leukemia ML-1 cells
were observed at 24 h, 48 h, and 72 h after exposure to daunorubicin
and its two formamidinodaunorubicin derivatives. At these three time
intervals, the cell viability, volume and count were assessed. 
The assays were conducted using the spectrophotometric 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assay and the electronic Beckman-Coulter method. In viable,
metabolically active cells, the tetrazolium ring of MTT is cleaved,
yielding formazan crystals. Changes in the metabolic activity of cell
populations result in a concomitant change in the amount of
formazan formed. The Beckman-Coulter method of cell sizing and
counting is based on the detection of an electrical pulse which
results from the passage of each cell through an aperture. The
amplitude of the produced electrical pulse depends on the cell
volume. The number of pulses indicates the cell count.
In vitro spectrophotometric MTT assay: MTT (Sigma-Aldrich) was
dissolved in RPMI 1640 medium, at a concentration of 5 mg/ml, and
filtered through a 0.2-μm filter. Subsequently, 100 μl of the yellow
MTT solution was added to each well of a 24-well plate, containing 
1 ml of the cell suspension. The cells were then incubated at 37˚C with
5% CO2. A blank solution was prepared according to the above
procedure using complete medium without cells. After a three-hour
incubation period, the resulting formazan crystals were dissolved with
1 ml of acidified isopropanol (0.05 N HCl in absolute isopropanol),
and the absorbance of the obtained solution was measured at
wavelength of 570 nm using a Pharmacia Ultrospec III spectropho-
tometer (Pharmacia LKB Biotechnology, Uppsala, Sweden). 
The half maximal inhibitory concentration (IC50) value
determination: The half maximal inhibitory concentration is 
a measure of the effectiveness of a compound in inhibiting
biochemical processes and biological functions. According to the in
vitro MTT assay, the IC50 represents the concentration of the tested
anthracycline agent that is required for 50% inhibition of the human
leukemia cell viability. Based on the obtained data using the in vitro
MTT assay, the IC50 values for daunorubicin and its two analogs,
DAUFmor and DAUFhex, calculated separately, at 72 h after the
human leukemia cells exposure to the anthracycline agents. To
determine the IC50 values, the concentration range used of each
antracycline was from 10-1,000 nM. 
Measurement of cell size and count: Samples of the acute leukemia
cell suspension (500 μl) were taken from flasks and immediately
diluted in 4.5 ml ISOTON II (Beckman-Coulter filtered electrolyte
solution based on 0.9% saline). After the dilution of the leukemia
cell suspension, individual cells were measured using a Z2 Coulter
counter (Beckman-Coulter, Miami, FL, USA). The volume and
count distribution of leukemia cells was obtained using a counter
equipped with a 100 μm diameter orifice. The flow rate was 500
μl/12.5 s. The range for MOLT-4 cell measurement was determined
as 65-3674 fL and for ML-1 cell measurement as 180-8181 fL. The
volume and count of MOLT-4 cells and ML-1 cells were analyzed,
respectively, at 402-3674 fL, and at 459-7346 fL. The instrument
was calibrated using 10 μm diameter latex beads (Beckman-Coulter
CC size standard). The mean cell volume and the cell count were
determined using Z2 AccuComp software (Beckman-Coulter,
Miami, FL, USA). 
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Figure 1. Chemical structures of daunorubicin (DAU), DAUFmor, and
DAUFhex. 
Statistical evaluation. Statistical significance of differences in the
amount of formazan formed, the IC50 value, and the cell volume and
count were evaluated by an analysis of variance and the Duncan’s
new multiple range test. A difference with p<0.05 was considered
statistically significant. The results were confirmed by three
independent experiments carried out in triplicate.
Results 
The effects of daunorubicin and its two new derivatives
DAUFmor, and DAUFhex on temporary changes in the acute
leukemia MOLT-4 and ML-1 cell viability (Figure 2), size
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Figure 2. Effects of daunorubicin (DAU), DAUFmor, and DAUFhex on the viability of MOLT-4 cells (A) and ML-1 cells (B). The extent of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) conversion to formazan in the acute leukemia cells reflects their viability. Values not
significantly different at p<0.05 according to the Duncan’s test: *, **, *** between the groups of leukemia cells treated with the anthracycline
agents; #compared to control; +between the time points. 
(Figures 3 and 4), and count (Figure 5) were compared. On
the basis of the obtained results, it can be generally stated that
the antileukemic activities of the new DAU analogs were
weaker than that of daunorubicin, and MOLT-4 cells were
more sensitive than ML-1 cells to the action of all agents
(Figures 2-5; Table I). Moreover, between the analogs,
DAUFmor appeared to be more active in ML-1 cells than
DAUFhex, as shown by the lower IC50 value found for
DAUFmor than DAUFhex (Table I). DAUFmor affected the
viability, volume and count of ML-1 cells to a greater degree
than did DAUFhex (Figure 2B, 3B, 4B, 5B). In the case of the
MOLT-4 cell exposure to the action of the DAU derivatives,
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Figure 3. Effects of daunorubicin (DAU), DAUFmor, and DAUFhex on the mean volume of MOLT-4 cells (A) and ML-1 cells (B). A decrease in the
cell volume can indicate that the cell can undergo apoptosis, and an increase of the cell volume can be associated with occurring mitotic catastrophe
or necrosis. Values not significantly different at p<0.05 according to the Duncan’s test: *, **, *** between the groups of leukemia cells treated with
the anthracycline agents; #compared to control; +between the time points. 
there was no difference between the IC50 values assessed for
DAUFmor and DAUFhex (Table I). Differences between the
viability, volume and count of MOLT-4 cells after application
of DAUFmor and DAUFhex were also not observed (Figure
2A, 3A, 4A, 5A).
The structural modifications of daunorubicin were
reflected in the different leukemia cell response to the action
of DAU and its two derivatives. The antileukemic potential
towards MOLT-4 cells and ML-1 cells depended on the agent
tested and its dose, the time interval after the anthracycline
application, and the cell line used (Figure 2- 5; Table I). 
Discussion
The two tested daunorubicin derivatives, DAUFmor and
DAUFhex, differ in the size of the cyclic amine ring in the
amidine group. Among the formamidinodaunorubicins, the
analog containing a six-membered morpholine ring with
heteroatom-oxygen in γ position in the formamidine group
appeared to be more active in ML-1 cells, while the analog
containing a seven-membered hexamethyleneimine ring with
CH2 group in the γ position was less active. These
daunorubicin analogs also differ because the DAUFmor
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Figure 4. The mean volume distribution curves of MOLT-4 cells (A) and ML-1 cells (B) recorded 72 h after exposure to the action of daunorubicin
(DAU), DAUFmor, and DAUFhex. The peaks on the left represent cellular debris, presumably apoptotic bodies and necrotic cell fragments, which
were excluded from the analysis of the MOLT-4 and ML-1 cell volume. 
molecule has an oxygen atom whereas DAUFhex has two CH2
groups. Moreover, due to the presence of the free electron
pairs on the oxygen atom, DAUFmor is capable of forming an
additional hydrogen bond with proton-donating sites, which
may also considerably alter its biological properties.
The various biological activities of formamidinoanthra-
cyclines and the parent antibiotics were also shown by
Wąsowska et al. (10-12). The results of these investigations
performed on the cancer cell lines, such as A549 (non-small
cell lung carcinoma), SW707 (colon adenocarcinoma), T47D
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Figure 5. Effects of daunorubicin (DAU), DAUFmor, and DAUFhex on the count of MOLT-4 cells (A) and ML-1 cells (B). Values not significantly
different at p<0.05 according to the Duncan’s test: *, **, *** between the groups of leukemia cells treated with the anthracycline agents; #compared
to control; +between the time points. 
(breast cancer) and HCV29T (urinary bladder cancer) point to
the varied action of anthracycline derivatives. It was also
demonstrated that among the various formamidinodauno-
rubicins, the derivative containing a six-membered ring in the
amidine group displayed greater activity against the different
cancer cell lines (10). 
Despite the findings of previous (10-12) and the present
investigations, the mechanisms of the biological action of the
new derivatives of daunorubicin and other anthracyclines on
malignant cells remain unclear. 
To summarize, the influence of the structure of DAU,
DAUFmor and DAUFhex on the temporary changes
occurring in the viability, size and count of MOLT-4 and
ML-1 cells was found. These are the first data comparing the
activities of DAU and the formamidinodaunorubicins which
in the amidine group either contain a morpholine moiety or
a hexamethyleneimine moiety, against the human acute
lymphoblastic and myeloblastic leukemia cells. 
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Table I. The half inhibitory concentration (IC50) values for
daunorubicin (DAU) and its two analogs DAUFmor and DAUFhex,
determined at 72 h after the exposure of MOLT-4 and ML-1 cells to the
action of the three anthracycline agents.
Human acute leukemia cell line
MOLT-4 ML-1
Agent IC50 ± SD (nM)
DAU    36.50±2.86 125.00±11.20
DAUFmor 85.17±3.33* 187.50±8.70
DAUFhex 85.58±3.09* 241.25±14.34
*Values not significantly different at p<0.05 according to the Duncan’s test. 
